AIMS: Restenosis in bare-metal stents is in part related to stent design and material. Optimized strut design of cobalt-chrome (CoCr) stents may yield nearly comparable results to drug-eluting stents (DES) in selected lesions. The prospective multicenter DaVinci registry investigates the clinical outcome of a CoCr coronary stent (MULTI-LINK VISION), particularly in terms of patients with diabetes and complex lesions (B1, B2, C). METHODS AND RESULTS: The prospective internet-based registry included 1,344 patients (76% males, aged 66 +/- 10 years) undergoing stent implantation (n = 1,642) in 32 centres from July 2003 to June 2004. Follow-up data (median 9 +/- 1 months) of this cohort were available for 1,289 patients (98.1%). Of these patients 327 (26.2%) were diabetics. In total, 1,429 de-novo lesions (A 11.9%, B1 47.7%, B2 31.6%, C 8.8%) were treated with the CoCr stent. The predefined primary endpoint was defined as a composite of death, Q-wave myocardial infarction (STEMI), non-STEMI (NSTEMI), target vessel revascularization (TVR) by coronary bypass graft (CABG) or PCI at 270 days (target vessel failure, TVF). Secondary endpoints include death, time to the first myocardial infarction, TVR and CABG. The cumulative incidence of major adverse cardiac events (MACE) was 12.4% with 0.8% deaths, 1.5% non-fatal MI, and 9.7% TVR. TVF in the overall cohort was documented in 137 (10.8%) patients. For diabetics and complex lesions TVF was 13.8% (95% CI 4.2-18) and 11.4% (95% CI 2.0-13.3), respectively. CONCLUSION: This large registry confirms good acute and long-term success of CoCr stents making this strategy valuable, particularly in a special cohort (diabetics and complex lesions) as long as late stent thrombosis with DES plays a role and short-term antiplatelet therapy is favoured.
AIMS: Restenosis in bare-metal stents is in part related to stent design and material. Optimized strut design of cobalt-chrome (CoCr) stents may yield nearly comparable results to drug-eluting stents (DES) in selected lesions. The prospective multicenter DaVinci registry investigates the clinical outcome of a CoCr coronary stent (MULTI-LINK VISION), particularly in terms of patients with diabetes and complex lesions (B1, B2, C). METHODS AND RESULTS: The prospective internet-based registry included 1,344 patients (76% males, aged 66 +/- 10 years) undergoing stent implantation (n = 1,642) in 32 centres from July 2003 to June 2004. Follow-up data (median 9 +/- 1 months) of this cohort were available for 1,289 patients (98.1%). Of these patients 327 (26.2%) were diabetics. In total, 1,429 de-novo lesions (A 11.9%, B1 47.7%, B2 31.6%, C 8.8%) were treated with the CoCr stent. The predefined primary endpoint was defined as a composite of death, Q-wave myocardial infarction (STEMI), non-STEMI (NSTEMI), target vessel revascularization (TVR) by coronary bypass graft (CABG) or PCI at 270 days (target vessel failure, TVF). Secondary endpoints include death, time to the first myocardial infarction, TVR and CABG. The cumulative incidence of major adverse cardiac events (MACE) was 12.4% with 0.8% deaths, 1.5% non-fatal MI, and 9.7% TVR. TVF in the overall cohort was documented in 137 (10.8%) patients. For diabetics and complex lesions TVF was 13.8% (95% CI 4.2-18) and 11.4% (95% CI 2.0-13.3), respectively. CONCLUSION: This large registry confirms good acute and long-term success of CoCr stents making this strategy valuable, particularly in a special cohort (diabetics and complex lesions) as long as late stent thrombosis with DES plays a role and short-term antiplatelet therapy is favoured.
Authors: Laura Mauri; Wen-hua Hsieh; Joseph M Massaro; Kalon K L Ho; Ralph D'Agostino; Donald E Cutlip Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: A Kastrati; J Mehilli; J Dirschinger; F Dotzer; H Schühlen; F J Neumann; M Fleckenstein; C Pfafferott; M Seyfarth; A Schömig Journal: Circulation Date: 2001-06-12 Impact factor: 29.690
Authors: Gregg W Stone; Jeffrey W Moses; Stephen G Ellis; Joachim Schofer; Keith D Dawkins; Marie-Claude Morice; Antonio Colombo; Erick Schampaert; Eberhard Grube; Ajay J Kirtane; Donald E Cutlip; Martin Fahy; Stuart J Pocock; Roxana Mehran; Martin B Leon Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Patrick W Serruys; Andrew T L Ong; Jan J Piek; Franz-Josef Neumann; Willem J van der Giessen; Marcus Wiemer; Andreas Zeiher; Eberhard Grube; Jürgen Haase; Leif Thuesen; Christian Hamm; Patricia C Otto-Terlouw Journal: EuroIntervention Date: 2005-05 Impact factor: 6.534
Authors: Paweł Buszman; Stanisław Trznadel; Aleksander Zurakowski; Krzysztof Milewski; Leszek Kinasz; Marek Król; Marek Kondys Journal: Kardiol Pol Date: 2007-09 Impact factor: 3.108
Authors: Alex Gabriele; Valeria Marco; Laura Gatto; Giulia Paoletti; Luca Di Vito; Fausto Castriota; Enrico Romagnoli; Andrea Ricciardi; Francesco Prati Journal: Int J Cardiovasc Imaging Date: 2014-06-14 Impact factor: 2.357